Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 178, Issue 10, 2008, Pages 1075-1082

  Doh, Hyung Kim ^a   Hee, Jin Kim ^b   Park, Seung Kyu ^c,d   Kong, Suck Jun ^e   Young, Sam Kim ^f   Kim, Tae Hyung ^g   Eun, Kyung Kim ^h   Ki, Man Lee ⁱ   Sung, Soon Lee ^j   Jae, Seuk Park ^a   Koh, Won Jung ^k   Lee, Chang Hoon ^l   Ji, Yeon Kim ^b   Tae, Sun Shim ^d,m  

^a Dankook University College of Medicine   (South Korea)

^b Korean Institute of Tuberculosis   (South Korea)

^c National Masan Hospital   (South Korea)

^d International Tuberculosis Research Center   (South Korea)

^e National Mokpo Tuberculosis Hospital   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g Hanyang University College of Medicine   (South Korea)

^h CHA University   (South Korea)

ⁱ Chungbuk National University College of Medicine   (South Korea)

^j Inje University   (South Korea)

^k Sungkyunkwan University School of Medicine   (South Korea)

^l Korea Centers for Disease Control and Prevention   (South Korea)

^m University of Ulsan College of Medicine   (South Korea)

more..

Author keywords

Extensively drug resistant tuberculosis; South korea; Treatment efficacy; Tuberculosis; Tuberculosis survival rate

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; ENVIOMYCIN; ETHAMBUTOL; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ACID FAST BACTERIUM; ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HAZARD RATIO; HEALTH SURVEY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOUTH KOREA; SPUTUM CULTURE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KOREA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 57349144559     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200801-132OC     Document Type: Article

References (35)

1. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003;362:887-899.
2. Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, Wells C, Nunn P, Blanc L, Raviglione M. Epidemiology of antituberculosis drug resistance (The Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006;368:2142-2154.
3. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-1580.
4. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, Williams BG, Dye C. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006;194:479-485.
5. World Health Organization. Global map and information on XDR-TB: countries with XDR-TB confirmed cases as of May 2008 [Internet] [accessed 2008 Aug 4]. Available from: http://www.who.int/tb/challenges/xdr/xdrmap_may08_en.pdf
6. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006;55:301-305.
7. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006;81:430-432.
8. Centers for Disease Control and Prevention. Extensively drug-resistant tuberculosis - United States, 1993-2006. MMWR Morb Mortal Wkly Rep 2007;56:250-253.
9. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, Lee JK, Kim SJ. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007;11:571-576.
10. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007;45:1290-1295.
11. Jeon CY, Hwang SH, Min JH, Prevots DR, Goldfeder LC, Lee H, Eum SY, Jeon DS, Kang HS, Kim JH, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 2008;46:42-49.
12. Seung KJ, Bai GH, Kim SJ, Lew WJ, Park SK, Kim JY. The treatment of tuberculosis in South Korea. Int J Tuberc Lung Dis 2003;7:912-919.
13. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, Iseman MD. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004;169:1103-1109.
14. Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, Hsu CJ, Suo J, Lin TP. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006;28:980-985.
15. Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova OS, Ferrara G, Cirillo DM, Gori A, Matteelli A, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007;30:623-626.
16. Migliori GB, Ortmann J, Girardi E, Besozzi G, Lange C, Cirillo DM, Ferrarese M, De Iaco G, Gori A, Raviglione MC. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis 2007;13:780-782.
17. Shim TS. Current situation of MDR-TB in Korea [abstract]. Presented at the fourth Korean-Swiss Biomedical Symposium June 6, 2007, Masan, South Korea:16-18.
18. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland: World Health Organization; 2006. Publication No. WHO/HTM/TB/2006.361.
19. Lew WJ, Lee EG, Bai JY, Kim HJ, Bai GH, Ahn DI, Lee JK, Kim SJ. An Internet-based surveillance system for tuberculosis in Korea. Int J Tuberc Lung Dis 2006;10:1241-1247.
20. National Tuberculosis Association. Diagnostic standards and classification of tuberculosis. New York: The Association; 1961.
21. Kim HJ, Hong YP, Kim SJ, Lew WJ, Lee EG. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int J Tuberc Lung Dis 2001;5:1129-1136.
22. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-532.
23. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blondal K, Caminero JA, Cegielski JP, Danilovits M, Espinal MA, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006;12:1389-1397.
24. Tahaoglu K, Torun T, Sevim T, Atac G, Kir A, Karasulu L, Ozmen I, Kapakli N. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001;345:170-174.
25. Kim HJ, Kang CH, Kim YT, Sung SW, Kim JH, Lee SM, Yoo CG, Lee CT, Kim YW, Han SK, et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur Respir J 2006;28:576-580.
26. National Tuberculosis Institute, Bangalore. Tuberculosis in a rural population of South India: a five-year epidemiological study. Bull World Health Organ 1974;51:473-488.
27. Leung CC, Lam TH, Chan WM, Yew WW, Ho KS, Leung G, Law WS, Tam CM, Chan CK, Chang KC. Lower risk of tuberculosis in obesity. Arch Intern Med 2007;167:1297-1304.
28. Perez-Guzman C, Vargas MH, Quinonez F, Bazavilvazo N, Aguilar A. A cholesterol-rich diet accelerates bacteriologic sterilization in pulmonary tuberculosis. Chest 2005;127:643-651.
29. Koenig R. Drug-resistant tuberculosis: in South Africa, XDR TB and HIV prove a deadly combination. Science 2008;319:894-897.
30. Chaisson RE, Martinson NA. Tuberculosis in Africa: combating an HIV-driven crisis. N Engl J Med 2008;358:1089-1092.
31. Oh MD, Choe K. Epidemiology of HIV infection in the Republic of Korea. J Korean Med Sci 1999;14:469-474.
32. Lee CH, Hwang JY, Bae JY, Kim HJ, Bae KH, Nam JK, Park BH, Kim HH. HIV/tuberculosis co-infection in Korea [abstract]. Tuberc Respir Dis 2007;61:62.
33. Choi BY. Perspectives of polices on HIV/AIDS and tuberculosis control in Korea. Korean J Epidemiol 2006;28:75-84.
34. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, Rich ML, Fraser HS, Alarcon E, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:640-645.
35. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baez J, Kochi A, Dye C, Raviglione MC. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000;283:2537-2545.